Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry. Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 ± 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy. Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.
362., R. P., Sota, J., Vitale, A., Lopalco, G., Iannone, F., Morrone, M., Giardini, H., D'Agostin, M., Antonelli, I., Almaghlouth, I., Asfina, K., Khalil, N., Sfikakis, P., Laskari, K., Tektonidou, M., Ciccia, F., Iacono, D., Riccio, F., Ragab, G., Hussein, M., Govoni, M., Ruffilli, F., Direskeneli, H., Alibaz-Oner, F., Giacomelli, R., Navarini, L., Bartoloni, E., Riccucci, I., Martín-Nares, E., Torres-Ruiz, J., Cipriani, P., Di Cola, I., Hernández-Rodríguez, J., Gómez-Caverzaschi, V., Dagna, L., Tomelleri, A., Makowska, J., Brzezinska, O., Iagnocco, A., Bellis, E., Caggiano, V., Gaggiano, C., Tarsia, M., Mormile, I., Emmi, G., Sfriso, P., Monti, S., Erten, Ş., Del Giudice, E., Lubrano, R., Conti, G., Olivieri, A., Lo Gullo, A., Tharwat, S., Karamanakos, A., Gidaro, A., Maggio, M., La Torre, F., Cardinale, F., Ogunjimi, B., Maier, A., Sebastiani, G., Opris-Belinski, D., Frassi, M., Viapiana, O., Bizzi, E., Carubbi, F., Fotis, L., Tufan, A., Kardas, R., Więsik-Szewczyk, E., Jahnz-Różyk, K., Fabiani, C., Frediani, B., Balistreri, A., Rigante, D., Cantarini, L., The administration of methotrexate in patients with Still’s disease, “real-life” findings from AIDA Network Still Disease Registry, <<SEMINARS IN ARTHRITIS AND RHEUMATISM>>, 2023; 2023 (62: 152244): 1-26. [doi:10.1016/j.semarthrit.2023.152244] [https://hdl.handle.net/10807/245235]
The administration of methotrexate in patients with Still’s disease, “real-life” findings from AIDA Network Still Disease Registry
Rigante, Donato;
2023
Abstract
Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry. Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 ± 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy. Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
